Navigation Links
Des défenseurs d'un traitement contestent un brevet pour un nouveau médicament contre l'hépatite C
Date:11/24/2013

NEW YORK, 25 novembre 2013 /PRNewswire/ -- Open Society Foundations a annoncé aujourd'hui que la demande de brevet de Gilead Science concernant son nouveau médicament, sofosbuvir, avait fait l'objet d'une contestation en Inde par l'Initiative for Medicines, Access & Knowledge.

Cette contestation, déposée la semaine dernière à l'Office des brevets de Calcutta, empêcherait Gilead de détenir le monopole de la production et de la tarification de sofosbuvir. Cela permettrait aux fabricants indiens de produire une version générique du médicament moins onéreuse, ce qui constituerait une première étape vers sa mise à disposition dans d'autres pays à faibles et moyens revenus.

Le traitement avec sofosbuvir est plus court que les traitements actuels, il présente des taux de guérison plus élevés, il peut être administré oralement et il est mieux toléré. Ces atouts ne sont cependant pas à la base d'un brevet. De plus, en Inde, la loi stipule que les produits qui sont des variantes de composés chimiques existants ne sont pas brevetables.

« Sofosbuvir n'est pas suffisamment innovant au niveau moléculaire pour justifier un brevet », explique Els Torreele, directeur de l'initiative « Access to Essential Medicines » d'Open Society Foundations. « Il s'agit d'une bataille à propos de la question de savoir si ce sont les profits ou la vie des patients qui guideront la lutte contre l'hépatite C ».

Sofosbuvir devrait être approuvé aux Etats-Unis et en Europe dans les prochaines semaines et pourrait coûter aux alentours de 80 000 dollars pour une série de traitements. Avec 90 % des personnes atteintes d'hépatite
'/>"/>

SOURCE Open Society Foundations
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. De nouvelles directives recommandent la fidaxomicine pour tous les patients pouvant suivre un traitement antibiotique par voie orale pour une infection à Clostridium difficile
2. Traitement du cancer primaire du foie : létude SARAH désormais accessible aux patients concernés sur lensemble du territoire français
3. Diagnostic et traitement du cancer : une encyclopédie gratuite en ligne
4. RuiYi et Genor BioPharma collaborent au développement du RYI-008 en Chine, un nouveau traitement contre les maladies auto-immunes et le cancer
5. Puritan Medical Products obtient deux nouveaux brevets en Australie pour ses écouvillons floqués
6. Un nouveau test moléculaire pour le dépistage pré-chirurgical détecte les souches MRSA récemment découvertes
7. MNX nomme un nouveau membre à son conseil dadministration, la société vise à accélérer sa croissance dans la logistique pour les domaines pharmaceutique et des essais cliniques
8. Après son lancement réussiaux États-Unis, le nouveau Simbionix U/S Mentor va être présenté pour la première fois en Europe
9. Nouveau Life Pharmaceuticals (NOUV) Releases Calcium & Vitamin D for Strong Bones
10. Nouveau Life Offers Potential Distributors Online Access to Company and Contract
11. Nouveau Life Pharmaceuticals (NOUV) Releases Krill Oil to Support Healthy Cholesterol Levels and Reduce Inflammation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 Intarcia ... interim clinical data for its lead candidate ITCA 650 ... patients with high baseline HbA1c levels at the 50 ... the Study of Diabetes (EASD). Data from the open-label, ... levels of blood sugar in patients with poorly controlled ...
(Date:9/19/2014)... , September 19, 2014 Reductions ... for many years in people with diabetes type 2 ... long term benefits for the kidneys." Australian ... with type 2 diabetes leads to persistent reductions in ... The global study has found that, five ...
(Date:9/18/2014)... Texas , Sept. 18, 2014  Low ... FDA committee meeting in Hyattsville, Maryland ... meeting to assess the proper patient population for ... potential cardiovascular risk associated with TRT. Examining recent claims ... committee found that "available epidemiological studies do not ...
Breaking Medicine Technology:Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 3Low T Center Endorses The Joint FDA Committee Meeting on Testosterone 2
... Africa, Dec. 23, 2011 Leatt Corporation (OTC: ... a neck brace system designed to help prevent potentially devastating ... announced that it held and webcast its 2011 Annual Meeting ... was present in person or by proxy. With ...
... 23, 2011 - Stupendous success on becoming Leader ... - Company,s main focus on ,Innovation & Creativity, ... Christmas present for Mr. Veeral Desai, Managing Director, Span Diagnostics ... nation,s most coveted ,ET NOW-IndiaMART Leaders of Tomorrow Awards 2011, ...
Cached Medicine Technology:Leatt Holds 2011 Annual Meeting of Shareholders 2Span Diagnostics Ltd. Hits Bull's eye at 'ET NOW-IndiaMART Leaders of Tomorrow Awards 2011' 2Span Diagnostics Ltd. Hits Bull's eye at 'ET NOW-IndiaMART Leaders of Tomorrow Awards 2011' 3
(Date:9/21/2014)... 21, 2014 “Cluster headaches are sometimes ... and difficult to resolve,” said Steve Young of Ew ... of a pain that is more intense.” , “It ... cluster headaches, or migraines, that medical research is pointing ... system,” he added. , Serotonin (5-HT, 5-hydroxytryptamine) is a ...
(Date:9/21/2014)... California (PRWEB) September 21, 2014 According to ... experienced the highest birth rate since 1966 (10.5 births per ... in their early 40s has risen steadily by 2 percent ... includes births to women aged 50 and over) also rose, ... that there were more than nine times as many first ...
(Date:9/20/2014)... 2014 Weight Destroyer , a ... expert Michael Wren that has already helped tens of ... health conditions like high blood pressure, high cholesterol, and ... prompting an investigative review. , “Weight Destroyer is ... down by showing people what is truly effective when ...
(Date:9/20/2014)... (PRWEB) September 21, 2014 Increases ... contributing to greater waste treatment volumes. However, government ... diverting waste from landfill. According to IBISWorld industry ... have implemented strategies aimed at reducing the volume ... waste recycled and recovered.” Still, a large proportion ...
(Date:9/20/2014)... The print component of “Work-Life ... the Calgary Herald, with a circulation of approximately ... The digital component is distributed nationally through a ... of top news sites and partner outlets. To ... http://www.worklifebalanceinfo.ca . , The publication features an ...
Breaking Medicine News(10 mins):Health News:Homeostasis: Equinox Serotonin (5HT) Headache Stories ~ New on the Bryan William Brickner Blog 2Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 2Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 3Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 4Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 2Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 3Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Getting ‘Wellthy’: Mediaplanet’s “Work-Life Wellness” campaign puts stock in the personal and economic gains of healthy, vital workplace environments for Canadians 2
... United American,Healthcare Corporation has nominated Bruce R. Galloway for ... Meeting of Shareholders scheduled,for Friday, November 7, 2008., ... shares of United,American Healthcare,s common stock, Lloyd I. Miller ... The proposal for the election of directors,is more fully ...
... 4 The National Patient Safety Foundation,(NPSF) today ... forum for leading health care solutions providers to ... and,patients and their families -- all with the ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080307/AQF053LOGO ), "We are excited ...
... the University of Pennsylvania School of Medicine can now ... mature B-cells in the blood stream at any one ... germs to fight infections. , "There is a steady ... for humans," says senior author Michael P. Cancro, PhD, ...
... arthritis now have many more treatment options than in ... drugs, derived by modifying substances found in humans or ... treating the symptoms. The cost of biologic DMARDs is ... cost 100 times more than a year,s supply of ...
... Pycnodysostosis, a condition from which the painter Henri de ... stature. This rare disease, surprisingly, provides a window into ... by deficiency of an enzyme known as cathepsin K ... in bone modeling and repair), leading to poor bone ...
... HOUSTON, Nov. 4 US Oncology today announced ... has,exceeded the $10 million mark in assisting more than ... Advantage in August 2006., "It was important when ... access to oral chemotherapies by easing the financial,burdens these ...
Cached Medicine News:Health News:AmerisourceBergen Joins National Patient Safety Foundation Corporate Council 2Health News:Penn scientists show how body determines optimal amount of germ-fighting B cells 2Health News:Medicaid policies vary widely for rheumatoid arthritis drugs 2Health News:Genetic disorder sheds light on enzyme's role in bone metabolism 2Health News:OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $10 Million Milestone in Patient Financial Assistance 2Health News:OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $10 Million Milestone in Patient Financial Assistance 3
... of emission at two different wavelengths (1064 and ... 1064 DW is able to select the delivered ... (with powers selectable among 4 and 100 W) ... 25 W). This second wavelength is very useful ...
Smartepil II is a laser particularly indicated for hair-removal where it has proved to be a valid instrument, even in the treatment of darker phototypes and telangiectasias of the face and legs....
... Tri-Active is the result of ... the combination of three different methods ... to your skin. This treatment is ... of cellulite through the combined action ...
... SmartOffice Plus is a CO2 ... to 25 W. Its functions in ... for surgery requiring extreme laser intervention ... in medical studios, it comes with ...
Medicine Products: